Pictet Asset Management (Switzerland)’s 10x Genomics TXG Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$589K	Buy	10,542 +1,224	+13%	+$66.2K	﹤0.01%	1163
2023 Q1	$520K	Hold	9,318	–	–	﹤0.01%	1234
2022 Q4	$340K	Buy	+9,318	New	+$305K	﹤0.01%	1426
2022 Q3	–	Sell	-209,595	Closed	-$9.48M	–	1619
2022 Q2	$9.48M	Sell	209,595 -20,141	-9%	-$1.04M	0.01%	612
2022 Q1	$17.5M	Sell	229,736 -35,479	-13%	-$3.1M	0.02%	522
2021 Q4	$39.5M	Buy	265,215 +127,422	+92%	+$19.5M	0.04%	391
2021 Q3	$20.1M	Buy	+137,793	New	+$23.7M	0.02%	513

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s TXG Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its 10x Genomics (TXG) stake by 13% in Q2 2023, buying an estimated $66.2K and bringing the position to 10,542 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

Pictet Asset Management (Switzerland) first reported a position in TXG in Q3 2021 and has held it in 7 quarters since. The position peaked at $39.5M in Q4 2021. 274 funds tracked by Wall St. Rank hold TXG as of Q2 2023.

Pictet Asset Management (Switzerland) held 10,542 shares of 10x Genomics worth $589K as of Q2 2023.
Pictet Asset Management (Switzerland) bought 1,224 10x Genomics shares in Q2 2023, an estimated $66.2K.
10x Genomics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1163 holding.
Pictet Asset Management (Switzerland) first reported a position in 10x Genomics in Q3 2021 and has held it in 7 quarters since.
Pictet Asset Management (Switzerland)'s 10x Genomics position peaked at $39.5M in Q4 2021.
274 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.